July 1, 2021/Cancer

National Ewing’s Sarcoma Tumor Board Connects Experts, Facilitates Discussion

How to get involved


Physicians treating patients with Ewing’s sarcoma will get a chance to discuss challenging cases with experts from Cleveland Clinic and other leading cancer centers throughout the country in a new National Ewing Sarcoma Tumor Board.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The board brings together a multidisciplinary group of specialists to review and discuss cases once a month. Its goal is to support physicians in rural or smaller hospitals by giving them access to expertise and resources from some of the nation’s foremost Ewing’s sarcoma specialists.

“We have a very strong sarcoma team and provide a large number of second opinions formally,” says Matteo Trucco, MD, a Cleveland Clinic pediatric oncologist who is leading the tumor board. “This is a way to help educate clinicians without as much experience with this rare tumor in an informal way.”

How it started

The project started with inspiration and support from foundations focused on Ewing’s sarcoma and motivated Cleveland Clinic’s sarcoma program to establish a more specialized Ewing’s sarcoma tumor board. Cleveland Clinic Cancer Center and Cleveland Clinic Children’s will be leading the effort, with experts from MD Anderson Cancer Center, Dana Farber Cancer Institute and other major cancer centers joining the panel. It’s the first tumor board of its kind in the United States.

“It’s really a team effort, inspired by patients,” Dr. Trucco says.

Ewing sarcoma is a rare cancer, affecting around 200 children and a handful of adults each year. Studies have found that patients who are treated by specialists at sarcoma centers tend to have better outcomes, but many cases are handled by oncologists at smaller regional or community hospitals. The tumor board is intended to help those physicians and patients, Dr. Trucco says.

How it works

As for who can submit a case for review by the board, Dr. Trucco says that patients who have relapsed multiple times, or who have medical complications that make them difficult to treat with the standard regimen would be good candidates.


“Those are the cases that require a little more discussion, a little more thought, a little more expertise, or they may require a surgery or radiation that may be a little trickier to deliver,” Dr. Trucco says. Cases must be submitted by the physician, he notes.

The board will have a secure portal through which the physician can submit an intake form describing the case, treatment so far, and what clinical question they wish to discuss. The board will review around four cases per month. The program is scheduled to launch on July 12, 2021. Virtual meetings will be held at 5 p.m. Eastern Time on the second Monday of each month.

Adult and pediatric medical oncologists, radiation oncologists, surgical oncologists, orthopedic tumor surgeons, and anyone else in the medical community with an interest in Ewing sarcoma is invited to attend. To protect patients’ privacy, meetings will not be open to patients or families of patients with Ewing’s sarcoma.

What to expect

The format for the meeting will include a slide presentation by the treating physician, providing background on the case and presenting pathology, scans, and molecular analysis of the tumor, if available. Discussion will follow with board members asking questions and offering ideas. Cases will be reviewed without any identifying information about the patient, he notes.

“Nothing is formal, no one will have seen the patient or reviewed the complete medical record, but we can offer some suggestions, some thoughts. ‘Have you thought about this? Have you looked at that?’ ‘Maybe reach out to this person who has a clinical trial nearby,’” Dr. Trucco says.

If the physician or family wants to pursue a formal consultation with Cleveland Clinic or any other institution after the review, that can be pursued separately, he adds.


The Cleveland Clinic Cancer Center is a leader in treating Ewing’s sarcoma, with some of the country’s top specialists in medical oncology, pediatric oncology, radiation oncology, orthopedic surgery and thoracic surgery, as well as one of the top pathology departments in the country for sarcomas.

For more information about the National Ewing Sarcoma Tumor Board, or to submit a case for review, visit https://redcap.link/ewing_ccf.

Editor’s note: This forum is for educational discussions only; it does not obviate the need for a second opinion or clinical consultation, and the presenting physician is solely responsible for the patient’s treatment plan.

Related Articles

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

microwave ablation of liver tumor
150-Watt, Single-Antenna Microwave Ablation System Demonstrates Safety and Efficacy

New device offers greater tumor control for malignant liver lesions

viral-induced cancer
April 3, 2024/Cancer
Mechanism of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) May Serve as Clue to More Effective Treatment

Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers
Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Cleveland Clinic physiatrist
March 22, 2024/Cancer/Innovations
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients